OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Mahon on the Importance of Integrating Genomic Science Into Oncology Practice

April 10th 2025

Suzanne Mahon DNS, RN, AOCN, AGN-BC, FAAN, discusses the importance of integrating genomic science into oncology practice.

Dr Andorsky on Molecular Responses With Second-Line Asciminib in CP-CML

April 10th 2025

David J. Andorsky, MD, discusses molecular responses achieved with asciminib dose escalation in patients with CP-CML who had received 1 prior TKI.

Dr Hamilton on Treatment Selection After Progression on Frontline CDK4/6 Inhibition in HR+ Breast Cancer

April 10th 2025

Erika P. Hamilton, MD, discusses how mutational profiles inform the management of HR-positive breast cancer after progression on a prior CDK4/6 inhibitor.

Dr Ahmed on the Rationale for Evaluating NTKR-255 After CAR T-Cell Therapy in R/R LBCL

April 10th 2025

Sairah Ahmed, MD, explains the rationale for evaluating NTKR-255 after CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Dr Lee on the Role of Integrative Medicine in Oncology Care

April 10th 2025

Richard Lee, MD, FASCO, discusses the role of integrative medicine in oncology care.

Dr Rampal on Personalizing Treatment Strategies for Patients With Myelofibrosis

April 10th 2025

Raajit Rampal, MD, discusses typical clinical applications of the 4 FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Dr Grisham on the Efficacy/Tolerability of Avutometinib Plus Defactinib in KRAS+ Serous Ovarian Cancer

April 10th 2025

Rachel N. Grisham, MD, discusses efficacy and tolerability data from the phase 2 ENGOT-OV60/GOG-3052/RAMP 201 subgroup analysis.

Dr Dholaria on the Rationale for Investigating P-BCMA-ALLO1 in R/R Myeloma

April 10th 2025

Bhagirathbhai Dholaria, MBBS, discusses the rationale and evolving investigation of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma.

Dr Bando on Safety of TAS-102 in MRD+ Resected CRC

April 9th 2025

Hideaki Bando, MD, PhD, discusses the safety of trifluridine/tipiracil in patients with MRD following resection of CRC.

Dr Escobar on CDK4/6 Inhibitor Selection in HR+ Metastatic Breast Cancer

April 9th 2025

Mauricio Escobar, MD, discusses CDK4/6 inhibitor selection based on retrospective real-world analyses in HR-positive metastatic breast cancer.

Dr Mateos on Ongoing Research With Cilta-Cel in Newly Diagnosed Multiple Myeloma

April 9th 2025

María-Victoria Mateos, MD, PhD, discusses next steps for evaluating the role of cilta-cel in lenalidomide-refractory and other multiple myeloma subtypes.

Dr Konstantinopoulos on Responses With Metformin Plus Letrozole/Abemaciclib in ER+ Endometriod Endometrial Cancer

April 9th 2025

Panagiotis A. Konstantinopoulos, MD, PhD, discusses CRs achieved with letrozole, abemaciclib, and metformin in ER–positive endometriod endometrial cancer.

Dr Lenz on the FDA Approval of Nivolumab Plus Ipilimumab for dMMR/MSI-H mCRC

April 8th 2025

Heinz-Josef Lenz, MD, discusses data from the CheckMate 8HW trial that led to the FDA approval of nivolumab plus ipilimumab for dMMR/MSI-H metastatic CRC.

Dr Dumbrava on the Rationale for Evaluating Rezatapopt in TP53 Y220C–Mutated Ovarian Cancer

April 8th 2025

Ecaterina Dumbrava, MD, discusses the rationale and clinical development of rezatapopt in ovarian cancer and other solid tumors harboring TP53 Y220C mutations.

Dr Yu on Factors for PARP Inhibitor Decision-Making in Metastatic Prostate Cancer

April 8th 2025

Evan Ya-Wen Yu, MD, discusses considerations surrounding the tolerability of PARP inhibitors and how their adverse effect profiles influence treatment decisions in metastatic prostate cancer.

Dr Shah on the Clinical Implications and Future Directions of Zamto-Cel in R/R DLBCL

April 8th 2025

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr Randall on a Survey Outlining Surgical Trial Candidates With RCC and Proximal Femoral Metastases

April 8th 2025

Lor Randall, MD, FACS, on a global survey regarding enrollment criteria for a trial evaluating surgical resection for proximal femur metastases.

Dr Kelly on Early Efficacy Signals and Safety With Sacituzumab Govitecan in Recurrent Glioblastoma

April 7th 2025

William Kelly, MD, discusses the safety and efficacy signals seen with sacituzumab govitecan in a phase 2 study of patients with recurrent glioblastoma.

Dr McCann on the Increasing Use of TKIs for HER2+ Breast Cancer Brain Metastases

April 7th 2025

Kelly E. McCann, MD, PhD, discusses the benefit of using TKI combinations for patients with HER2-positive breast cancer and brain metastases.

Dr Zonder on the Epidemiology of Multiple Myeloma

April 7th 2025

Jeffrey Zonder, MD, discusses the current epidemiological landscape of multiple myeloma in the United States.